Breast Cancer
Conditions
Keywords
pretreated metastatic breast cancer
Brief summary
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment
Detailed description
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment that would have the theoretical advantage of being well tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.
Interventions
DRUGVinorelbine
Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
DRUGLetrozole
Lestrozole at 2,5 mg every day , per oral
DRUGAnastrozole
Anastrozole at 1 mg every day, per oral
Sponsors
Pierre Fabre Laboratories
ARCAGY/ GINECO GROUP
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
50 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 50 years. 2. Histologically proven breast cancer. 3. Progesterone and /or oestrogene receptors positive. 4. HER2 negative on primary tumour. 5. Patient taking hormonotherapy, in progression, already treated by at least one line of anti-aromatase non-steroidal hormonotherapy and by at least on line of chemotherapy. 6. Patient having to begin a second or third line of chemotherapy. 7. Presence of one or several measurable(s) or assessable(s) metastatic lesion(s).In case of isolated bone lesion (s): need to have a non-irradiated with an osteolytic component for be considered as lesion (s) target (s) and having an elevation of the CA15-3. 8. Post menopausal woman. 9. ECOG 0, 1 or 2. 10. Adequate biological function. * Neutrophil ≥ 1,5.E9/L * Platelets ≥ 100.E9/L * Creatinine clearance ≥ 30 mL/min * Total bilirubin ≤ 1,5 x the upper limit of normal (ULN) * Alkaline phosphatase ≤ 2,5 x ULN * ALT, AST ≤ 1,5 x ULN in the absence of liver metastases or ≤ 3 x ULN if liver metastases. 11. Patient with a life expectancy greater than 3 months. 12. Signed informed consent before enrollment. 13. affiliation to a social security scheme
Exclusion criteria
1. Patient with located or single metastatic tumoral relapse, accessible to a surgical treatment. 2. Patient having already received more 2 lines of chemotherapy for metastatic or advanced decease 3. Patient having already received a treatment by Navelbine® 4. Patient requiring an immediate located radiotherapy for analgesic action 5. Patient with non-irradiated cerebral or symptomatic metastasis, symptomatic pulmonary carcinomatosis lymphangitis 6. Simultaneous administration of another chemotherapy hormonotherapy or anti-tumoral drug 7. Patient having already received another treatment ongoing evaluation within the 30 days before the screening visit 8. Known positive serology HIV 9. Previous cancer within 5 years before the entry in the study, excepted an in situ carcinoma of the cervix or a spino or basal cell carcinoma of the skin or a nonmelanoma skin cancer with an adequate treatment. 10. Any serious concomitant pathology and / or uncontrolled could compromise participation in the study (including uncontrolled diabetes, uncontrolled hypertension, severe infection, profound malnutrition, unstable angina or congestive heart failure - class III or IV according to the New York Heart Association - ventricular arrhythmias, progressive coronary artery disease, myocardial infarction within the last six months, chronic liver or kidney disease, a progressive ulceration of the digestive tract above, CNS disorders). 11. Disorder of gastrointestinal function (GI) or pathology likely to significantly interfere with the absorption of Navelbine, of Letrozole or Anastrozole (eg. Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, syndrome malabsorption, or resection of the small intestine). 12. Known hypersensitivity to letrozole, anastrozole, vinorelbine or other vinco-alkaloids or any other component. 13. Patient with fructose intolerance, galactose, a Lapp lactase deficiency or malabsorption of glucose and galactose (rare hereditary disease). 14. Patient with a history of poor compliance with medical treatment. 15. Patient can not be monitored regularly for family reasons, geographical, social or psychological. 16. Patient with altered mental status would not allow him to understand the study or give informed consent .
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | up to 6 months | Proportion of progression or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of partial and complete response rate by RECIST 1.1 | up to 6 months | partial and complete response rate by RECIST 1.1 in each arm |
| clinical benefit after 24 weeks of treatment | up to 24 weeks | the clinical benefit is defined by the rate of complete response, by the rate of partial response and by the stability of lesions at 24 weeks according to criteria RECIST 1.1 |
| duration of response | up to 6 months | duration of response is defined as the time from randomization and the disease progression |
| Toxicity according to criteria NCI CTAEv4.03 | up to 2 years | tolerance of the treatment based on AE occurrence according to criteria NCI CTAEv4.03 |
| health-related quality of life | up to 2 years | health-related quality of life and symptomatic state will be evaluated by filling a questionnaire by patients |
| overall survival | up to 2 years | the overall survival of patients randomized is defined as the time from randomization and the date of death |
Countries
France
Outcome results
None listed